Literature DB >> 23506097

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study.

Luciano Levato, Renato Cantaffa, Maria Grazia Kropp, Domenico Magro, Eugenio Piro, Stefano Molica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23506097     DOI： 10.1111/ejh.12096

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  22 in total

Review 1.  An update on cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman
Journal:  Trends Cardiovasc Med       Date:  2014-07-22       Impact factor: 6.677

Review 2.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 3.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 4.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 5.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

6.  Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Authors:  Preetesh Jain; Hagop Kantarjian; Prajwal C Boddu; Graciela M Nogueras-González; Srdan Verstovsek; Guillermo Garcia-Manero; Gautam Borthakur; Koji Sasaki; Tapan M Kadia; Princy Sam; Hycienth Ahaneku; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Jorge E Cortes
Journal:  Blood Adv       Date:  2019-03-26

Review 7.  Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.

Authors:  Mary C Barber; Michael J Mauro; Javid Moslehi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Authors:  Javid J Moslehi; Michael Deininger
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

9.  Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.

Authors:  E Bondon-Guitton; S Combret; M C Pérault-Pochat; M Stève-Dumont; H Bagheri; F Huguet; F Despas; A Pathak; J L Montastruc
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.